Navigation Links
Top-line Data From Phase 3 Trial of Ataluren in Patients with Nonsense Mutation Cystic Fibrosis Show Promising Results
Date:6/8/2012

oncomitant treatment with systemic aminoglycosides.

Patients with CF lack adequate levels of the CFTR protein, a chloride channel necessary for normal function of the lung, pancreas, liver and other organs. In nmCF, an interruption in the genetic code - known as a nonsense mutation - prematurely halts the synthesis of CFTR, causing the protein to be short and non-functioning. Nonsense mutations are categorized as Class I mutations that result in little or no production of the CFTR protein. CF patients with Class I mutations typically experience more severe disease symptoms than those with other genotypes, including a shorter life span, a higher probability of end-stage lung disease, and a higher prevalence of pancreatic insufficiency. Ataluren, a protein restoration therapy, is designed to overcome the nonsense mutation and enable the production of a full-length, functional CFTR protein. A simple genetic test can determine if a patient's disease is caused by a nonsense mutation.

"PTC has a long-standing commitment to discovering and developing new treatments for rare, life-threatening disorders such as cystic fibrosis. We are very encouraged by the data from our trial, which was a long-term placebo-controlled study of a CFTR corrector targeting nonsense mutations," stated Stuart W. Peltz, Ph.D., Chief Executive Officer of PTC Therapeutics, Inc. "The results in the patients not on inhaled aminoglycosides are particularly promising. Substantial differences between ataluren and placebo in mean relative change in %-predicted FEV1 and pulmonary exacerbation rate were demonstrated and the fact that both endpoints improved is a strong indicator of ataluren's activity."

About the Phase 3 TrialThe primary objective of the double-blind, placebo-controlled study was to determine whether ataluren can improve lung function relative to placebo in patients with nonsense mutation cystic fibrosis, as measured by forced expiratory volume in 1 second (FE
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Amgen Announces Top-Line Results Of Phase 3 Sensipar®/Mimpara® EVOLVE™ Trial
2. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
3. Lilly and Incytes Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis
4. Sorrento Therapeutics Awarded Third Phase I STTR Grant
5. Taiho Pharmaceutical Announces Start of Global Phase III Clinical Trial in Metastatic Colorectal Cancer with Novel Antitumor Agent TAS-102
6. Interim Results Reported for Phase I Open-Label Clinical Trial for the Treatment of PTSD and MDD Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
7. Flexions Lead Osteoarthritis Drug Candidate Demonstrates Significant, Prolonged Improvement in Pain and Function in Phase 2 Trial
8. Marshall Edwards Announces First Cohort Of Patients Dosed In Phase I Clinical Trial Of Oncology Drug Candidate ME-344
9. Preliminary Phase 2 Data of Ocera Therapeutics OCR-002 for the Treatment of Liver Cirrhosis and Upper GI Bleeding Show Potent Ammonia Reduction
10. Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers
11. Clinilabs Opens Phase I Unit In Eatontown, New Jersey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Investor-Edge has initiated coverage on the ... Pharma PLC (NASDAQ: HZNP ), Endocyte Inc. (NASDAQ: ... JNJ ), and Theravance Inc. (NASDAQ: THRX ). ... http://investor-edge.com/register . On Tuesday, November 25, 2014, ... Jones Industrial Average edged 0.02% lower, to finish the day ...
(Date:11/26/2014)... , November 26, 2014 A ... of the organ protrudes through the wall of a weak ... area at birth are some of the causes of hernias. ... hiatal, femoral, and incisional. An inguinal hernia is when part ... umbilical hernia is found in the area of the umbilicus. ...
(Date:11/26/2014)... 2014  Aridis Pharmaceuticals, Inc., a biopharmaceutical company ... infectious diseases, announced today the addition of ... opinion leader in the areas of pneumonia and ... Founder and Chief Executive Officer, Vu ... extensive experience investigating bacterial toxins and key mechanisms ...
Breaking Medicine Technology:Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5Global Hernia Repair Devices Market Size, Share, Trends and Forecast 2014 to 2018 - Big Market Research 2Global Hernia Repair Devices Market Size, Share, Trends and Forecast 2014 to 2018 - Big Market Research 3Global Hernia Repair Devices Market Size, Share, Trends and Forecast 2014 to 2018 - Big Market Research 4Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 2Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 3
... dependent on opioids (narcotic pain relievers) for pain management ... difficulty recovering, a study recently published in the Journal ... found. These patients tend to have longer hospital stays, more ... likely to need additional procedures, than patients who are not ...
... Nov. 11, 2011 It,s a well known metric in ... to fill a prescription after initially receiving a sample from ... evolving as the traditional sampling conduit - sales reps - ... counts. In this environment, many pharmaceutical companies ...
Cached Medicine Technology:Take Care with Pain Meds 2Take Care with Pain Meds 3Current Trends and Future Directions in Physician E-Sampling Programs for the Pharmaceutical Industry 2
(Date:11/27/2014)... New York, New York (PRWEB) November 27, 2014 ... http://www.risperdallawsuit2014.com/ ) have been filed in a ... Bernstein Liebhard LLP reports. , Documents recently ... show 1,079 records included in the state proceeding, ... treat schizophrenia, bipolar disorder and other psychiatric conditions. ...
(Date:11/27/2014)... Dennis Thompson HealthDay Reporter ... experimental Ebola vaccine appears to be safe and produces an ... virus, according to early clinical trial results reported by the ... phase I clinical trial for the vaccine paves the way ... Liberia and Sierra Leone as early as January, said Dr. ...
(Date:11/27/2014)... (PRWEB) November 27, 2014 The founders of ... stylish, comfortable and high functioning compression socks, are proud to ... socks use an innovative Gradient Pressure (TM) knitting technology that ... , VIM & VIGR’s commitment to adding flair and style ... just functional recently caught the eye of a writer at ...
(Date:11/27/2014)... New York, New York (PRWEB) November 27, 2014 ... behalf of individuals who were allegedly injured by the ... court, where a federal litigation is looking ahead to ... , According to a Scheduling Order issued earlier ... take place on December 16th at 10:00 a.m. Items ...
(Date:11/27/2014)... “Wekho” was featured on NewsWatch as part of ... applications on the iOS, Android, and Windows markets. Andrew Tropeano, ... app review and shared with viewers how it ... interesting new way to travel and experience the world has ... called Wekho and it’s a free geolocation app that lets ...
Breaking Medicine News(10 mins):Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 2Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 3Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 4Health News:Early Trial Promising for Ebola Vaccine 2Health News:Early Trial Promising for Ebola Vaccine 3Health News:VIM & VIGR Announces Launch of Men’s Line of Compression Socks 2Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 2Health News:Federal Litigation Presiding over Tylenol Lawsuits Looks Ahead to Status Conference in December, Bernstein Liebhard LLP Reports 3Health News:A New Geolocation Mobile Application and was Featured on NewsWatch Television on October 30, 2014 2
... a booster vaccination against H5N1 avian influenza given years after ... controlling a potential future pandemic. The study is published ... Infectious Diseases, now available online. , H5N1 continues to ... of mid-June, more than 60 percent of the more than ...
... ADDitude magazine,s top scientific,advisors investigate and explain non-drug ... green time and neurofeedback -,that may relieve ADHD ... how,nutrition, exercise and supplements can help treat ADHD ... magazine, the leading,publication for families and adults living ...
... boost,disability field,s quest to tie in public funding ... 16 One of the most complex,issues in ... and fund,services equitably to people with intellectual and ... Intensity Scale (SIS),assessment tool, developed by the American ...
... days of summer are here, and,for many, the rising ... an,estimated 40 percent of children and 20 percent of ... are spending three billion,dollars a year on antihistamines, often ... say in-vitro blood tests, the,latest generation of allergy tests, ...
... to irregular patterns of light and darkness can cause ... with the 24-hour solar day, negatively affecting human health ... the relationship between circadian disruptions and human maladies. ... Institute,s Lighting Research Center (LRC) provides a new framework ...
... Amsterdam, 16 July 2008 Elsevier, a leading publisher of ... Urology , the official journal of the European Association ... 5.634. , European Urology (also ... papers, fast response and an international profile. To keep up ...
Cached Medicine News:Health News:Booster vaccination may help with possible future avian influenza pandemic 2Health News:Booster vaccination may help with possible future avian influenza pandemic 3Health News:Treating ADHD Symptoms Without Medication: Free Special Report Examines Alternative ADHD Treatments 2Health News:The Supports Intensity Scale Assessment Can be Used to Build Robust Funding Methods for Developmental Disability Services, New Research Reveals 2Health News:New approach sheds light on ways Circadian disruption affects human health 2Health News:New approach sheds light on ways Circadian disruption affects human health 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: